Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 4/20 | 0.34 |
| ▸ | RXRB | P28702 | 4/20 | 0.34 |
| ▸ | RXRG | P48443 | 3/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9115008 | 0.90 | BCL2L1 (0.38) | BCL2L1BADTBXA2RDHFRALDH1A1 | |
| SCHEMBL9110395 | 0.85 | BCL2L1 (0.42) | BCL2L1BADTSHRTBXA2RDHFR | |
| SCHEMBL2093920 | 0.85 | BCL2L1 (0.36) | BCL2L1BADTBXA2RDHFRALDH1A1 | |
| SCHEMBL9720039 | 0.85 | BCL2L1 (0.54) | BCL2L1BADTSHRTBXA2RDHFR | |
| SCHEMBL2099150 | 0.84 | BCL2L1 (0.38) | BCL2L1BADTBXA2RDHFRSMN1; SMN2 | |
| SCHEMBL29356330 | 0.82 | ALDH1A1 (0.44) | BCL2L1BADTSHRTBXA2RDHFR | |
| SCHEMBL11355027 | 0.82 | BCL2L1 (0.48) | BCL2L1BADTSHRTBXA2RDHFR | |
| SCHEMBL6256898 | 0.82 | ALDH1A1 (0.44) | BCL2L1BADTSHRTBXA2RDHFR | |
| SCHEMBL6003271 | 0.81 | BCL2L1 (0.38) | BCL2L1BADTBXA2RDHFRALDH1A1 | |
| SCHEMBL6542314 | 0.81 | MEN1 (0.43) | BCL2L1BADTBXA2RALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | claimed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | claimed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| US-6844318-B2 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1263473-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001068145-A2 | PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC DRUGS AND THEIR THERAPEUTIC USE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103133-A1 | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use | DNPEP, TMPRSS15, ENPEP | BCL2L1 810/4885BAD 428/4885TSHR 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.